Priapism: An Avoidable Complication of Pharmacologically Induced Erection
- 1 October 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 142 (4) , 995-997
- https://doi.org/10.1016/s0022-5347(17)38965-6
Abstract
Priapism is an alarming complication during treatment of erectile dysfunction with vasoactive drugs, particularly papaverine alone or in combination with phentolamine mesylate. An investigational protocol was designed to identify patients who are more susceptible to priapism after intracavernous injection of papaverine alone or with phentolamine. The protocol was applied in 331 men with impotence of various etiology. The association of a positive response to visual sexual stimulation and penile brachial index of more than 0.8 represented a higher risk for post-injection priapism. We were able to reduce the incidence of this compliance to 1% in the last 101 patients.This publication has 5 references indexed in Scilit:
- New methods in the diagnosis of impotence: RigiScan® penile tumescence and rigidity monitoring and diagnostic papaverine hydrochloride injectionWorld Journal of Urology, 1987
- Pharmacological Erection: Diagnosis and Treatment Applications in 69 PatientsJournal of Urology, 1987
- Urethral Stricture Following Cardiovascular Surgery: Role of Urethral IschemiaJournal of Urology, 1986
- Evoked potential of the sacral arc reflex: Technical aspectsNeurourology and Urodynamics, 1986
- Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic ImpotenceJournal of Urology, 1985